455 On Other Exchanges
455 is not on other exchanges.

tianda pharmaceuticals ltd (455) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TIANDA PHARMACEUTICALS LTD (455)

Related News

No related news articles were found.

tianda pharmaceuticals ltd (455) Related Businessweek News

No Related Businessweek News Found

tianda pharmaceuticals ltd (455) Details

Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products. It offers cardio-cerebrovascular, pediatric, cold and respiratory system, anti-infective, and detoxification drugs, as well as complementary health care products comprising bone health, heart health, immune booster, nutritional oil, vitamin and mineral, women’s nutrition, wellbeing, and personal care products. The company also provides medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. It primarily operates in the People’s Republic of China, Hong Kong, and Australia. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. Tianda Pharmaceuticals Limited is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.

425 Employees
Last Reported Date: 07/19/16

tianda pharmaceuticals ltd (455) Top Compensated Officers

Managing Director and Executive Director
Total Annual Compensation: $1.5M
Compensation as of Fiscal Year 2016.

tianda pharmaceuticals ltd (455) Key Developments

Tianda Pharmaceuticals Limited Declares a Final Dividend

Tianda Pharmaceuticals Limited approved a final dividend of 0.27 HK cents per share at the annual general meeting of the Company held on 18 August 2016.

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 18, 2016

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 18, 2016, at 10:30 China Standard Time. Location: Suites 2405-2410, 24th Floor CITIC Tower, No. 1 Tim Mei Avenue Central Hong Kong Agenda: To consider the audited consolidated financial statements, the report of the directors and the independent auditor's report of the company for the year ended 31 March 2016; to declare a final dividend of 0.27 HK cent per share; to re-elect executive Director, non-executive Director and independent non-executive Directors; to authorise the board of directors to fix the Directors' remuneration for the year ending 31 March 2017; to re-appoint Deloitte Touche Tohmatsu as auditor and to authorise the Board of directors to fix the remuneration of auditor; to consider the exercise by the directors of the company during the relevant period of all the powers of the company to repurchase shares of HKD 0.10 each in the capital of the company on The Stock Exchange of Hong Kong Limited; and to consider other things.

Tianda Pharmaceuticals Limited Proposes Final Dividend for Fiscal Year Ended March 31, 2016, Payable on August 31, 2016; Reports Consolidated Earnings Results for the Year Ended March 31, 2016

The Board of Directors of Tianda Pharmaceuticals Limited recommended the payment of a final dividend of HK 0.27 cent per share for fiscal year ended March 31, 2016 against nil a year ago. Subject To Approve the shareholders at the AGM, the proposed final dividend will be payable to the shareholders whose names appear on the register of members of the company on August 31, 2016 and the register of members of the company will be closed from August 29, 2016 to August 31, 2016, both days inclusive, during which period no transfer of shares will be effected. The company reported consolidated earnings results for the year ended March 31, 2016. For the year, the company reported revenue of HKD 192,784,764 against HKD 139,366,849 a year ago. Profit before tax was HKD 18,424,870 against loss before tax of HKD 24,261,675 a year ago. Profit for the year attributable to owners of the company was HKD 6,568,591 or 0.32 cents per basic share against loss for the year attributable to owners of the company of HKD 17,941,969 or 0.96 cents per basic share a year ago.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

455 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 455.
View Industry Companies

Industry Analysis


Industry Average

Valuation 455 Industry Range
Price/Earnings 100.0x
Price/Sales 5.8x
Price/Book 1.4x
Price/Cash Flow 170.2x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TIANDA PHARMACEUTICALS LTD, please visit www.tiandapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.